| __timestamp | Amneal Pharmaceuticals, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 10811000 |
| Thursday, January 1, 2015 | 109679000 | 33001000 |
| Friday, January 1, 2016 | 118757000 | 64936000 |
| Sunday, January 1, 2017 | 109046000 | 99909000 |
| Monday, January 1, 2018 | 230435000 | 127724000 |
| Tuesday, January 1, 2019 | 289598000 | 161524000 |
| Wednesday, January 1, 2020 | 326727000 | 182933000 |
| Friday, January 1, 2021 | 365504000 | 219982000 |
| Saturday, January 1, 2022 | 399700000 | 278139000 |
| Sunday, January 1, 2023 | 429675000 | 309799000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. This chart offers a decade-long glimpse into the Selling, General, and Administrative (SG&A) expenses of Amneal Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. From 2014 to 2023, Amneal's SG&A costs surged by over 400%, reflecting its aggressive expansion and market penetration strategies. In contrast, Ultragenyx, a pioneer in rare disease treatments, saw its expenses grow by nearly 300%, underscoring its commitment to innovation and research.
By 2023, Amneal's SG&A expenses were approximately 39% higher than Ultragenyx's, highlighting its larger operational scale. This financial narrative not only showcases the strategic priorities of these companies but also offers insights into their market positioning. As the pharmaceutical industry continues to evolve, such financial metrics will remain pivotal in assessing corporate health and strategic direction.
Breaking Down SG&A Expenses: Sanofi vs Amneal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Amneal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Perrigo Company plc Trends and Insights
SG&A Efficiency Analysis: Comparing Amneal Pharmaceuticals, Inc. and MiMedx Group, Inc.
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.